Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.

Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, Henney HR 3rd, Blight AR; MS-F203, MS-F204, and Extension Study Investigators.

Mult Scler. 2015 Sep;21(10):1322-31. doi: 10.1177/1352458514563591. Epub 2015 Jan 12.

2.

Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.

Coleman CI, Sobieraj DM, Marinucci LN.

Curr Med Res Opin. 2012 Jan;28(1):49-56. doi: 10.1185/03007995.2011.639752. Epub 2011 Nov 23.

PMID:
22073939
3.

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.

Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR; MSF204 Investigators.

Ann Neurol. 2010 Oct;68(4):494-502. doi: 10.1002/ana.22240.

PMID:
20976768
4.

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.

Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F203 Investigators.

Lancet. 2009 Feb 28;373(9665):732-8. doi: 10.1016/S0140-6736(09)60442-6.

PMID:
19249634
5.

Dose comparison trial of sustained-release fampridine in multiple sclerosis.

Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F202 Study Group.

Neurology. 2008 Oct 7;71(15):1134-41. doi: 10.1212/01.wnl.0000326213.89576.0e. Epub 2008 Jul 30.

PMID:
18672472
6.

Effects of aging, diet, and sex on plasma glucose, fructosamine, and lipid concentrations in barrier-raised Fischer 344 rats.

Van Liew JB, Davis PJ, Davis FB, Bernardis LL, Deziel MR, Marinucci LN, Kumar D.

J Gerontol. 1993 Sep;48(5):B184-90.

PMID:
8366257

Supplemental Content

Loading ...
Support Center